A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Early man first invented tools. Then he invented jewellery. Archeologists have discovered strings of shells, believed to have ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...